Skip to content

Intervention for Intrusive Negative Thinking

Graduated Sensory Salience as an Intervention for Intrusive Negative Thinking

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02394704
Enrollment
194
Registered
2015-03-20
Start date
2015-11-01
Completion date
2021-08-17
Last updated
2021-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrusive Negative Thinking

Keywords

Rumination, Sensory processing, Non-pharmacological intervention, Depression, Anxiety, PTSD

Brief summary

Intrusive negative thinking styles such as rumination are typical of many psychiatric disorders, are difficult to treat, and predict poor treatment outcome. The investigators propose to evaluate a new intervention for negative thinking that capitalizes and builds on the preserved ability to attend to physical sensation. The investigators will examine changes in physiological mechanisms and symptoms.

Detailed description

Intrusive negative cognitions are key features of many psychiatric disorders, are difficult to treat, and predict poor outcomes in conventional and neurobehavioral interventions. Here, we evaluate the extent to which a novel intervention capitalizing on a preserved neurocircuitry for attending to evolutionarily salient somatosensory stimuli can be used to train attentional mechanisms to override otherwise pre-potent negative cognitions. The initial period will involve open-label intervention refinement and mechanistic evaluation of mechanism; N=35 individuals with high levels of intrusive negative cognitions and dysphoria will be assessed pre/post intervention in the graded sensory training condition. Success will suggest a new intervention pathway for a traditionally treatment-resistant dimension of psychopathology. The second phase will be a randomized trial of 70 participants equally allocated to graded and non-graded training conditions.

Interventions

OTHERSensory attention training

Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks.

Sponsors

Liberos LLC
CollaboratorINDUSTRY
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

for all participants: * Signed study consent document * Native English speakers (learned English before age 5) * Right handed * 20/30 vision or better * Free from benzodiazepines and betablockers within 8 hours of evaluations Subject specific Inclusion Criteria * Endorsement of chronic and intrusive negative thinking * High scores on rumination; Response Style Questionnaire (RSQ \>= 44) * Automatic Negative Thoughts Questionnaire (ATQ \>= 48) * Dysphoria; Quick Inventory of Depressive Symptomatology (QIDS\>= 8) * Must be in current treatment (either Intensive Outpatient Therapy, regular therapy sessions with a licensed provider, or close care by a psychiatrist). This is to ensure the research team is not the patient's only care provider, as this intervention is intended to be adjunct with therapy.

Exclusion criteria

* Refusal or inability to provide informed consent * Current alcohol or substance dependence * Psychotic disorders or psychosis * Neurological disorders (stroke, Alzheimer's, Parkinson's, epilepsy, etc.) * Inability to complete questionnaires in English. The justification is that many of the primary analyses involve assessment of change in self-reported symptoms using measures normed in English. Participants must thus be able to read those measures to give valid indications of the extent to which they have responded to the intervention. * Current use of any psychotropic drugs thought to affect learning, including antipsychotics, anticonvulsants, stimulants, and anti-Parkinsonian drugs. Current is defined as within 2 weeks of testing, 4 weeks for fluoxetine. * Chronic pain that could be exacerbated by transcutaneous electrical stimulation * Having any eye problems or difficulties in corrected vision or hearing * Having a North American Adult Reading Test (NAART) equivalent Full Scale Intelligence Quotient \< 85 * Being pregnant. Determined by self-report at the interview and by a pregnancy test * Severe or poorly controlled concurrent medical disorders that may cause thinking disruptions or require medication that could cause negative thinking * Current use of medications that could cause affect thinking symptoms. That is, participants need to be able to think clearly to complete the proposed information processing tasks. And they need to be able to learn to be able to make use of the intervention. Medications which compromise clear thinking or which block learning will thus be considered

Design outcomes

Primary

MeasureTime frameDescription
Sustained attention composite (computer based tasks and physiological measures)two weeks (five intervention days)Sustained attention is operationalized by performance on computer-based tasks (sensitivity, reaction times) and associated physiological measures (pupil dilation, eye movements, heart rate, EEG) and central measures (fMRI derived reactivity in affect, somatosensory, and attention networks). These metrics will be interpreted together as a meta-analytic composite by counting the number of component measures with significant change in association with the intervention in comparison to a permutation-test derived critical number of indices change under the null hypothesis given the autocorrelation of the administered measures.

Secondary

MeasureTime frameDescription
Rumination (patient self-report)two weeks (five intervention days)Clinical variables determined by patient self-report.
Depressive severity (patient self-report)two weeks (five intervention days)Clinical variables determined by patient self-report.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026